- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00989391
A Study In Healthy People To Investigate The Safety, Toleration And Time Course Of Blood Concentrations Of Multiple Doses Of PF-03654764, Given By Mouth
15. december 2009 opdateret af: Pfizer
A Double Blind (3rd Party Open), Randomized, Placebo Controlled, Dose Escalation Study To Investigate The Safety, Toleration, And Pharmacokinetics Of Multiple Oral Doses Of PF-03654764 In Healthy Subjects
The purpose of this study in heathy people is to investigate the safety, toleration and time course of PF-03654764 in the blood, following multiple doses given once or twice daily by mouth for 10 days.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
36
Fase
- Fase 1
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
-
Singapore, Singapore, 188770
- Pfizer Investigational Site
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
21 år til 55 år (Voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Healthy subjects. (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests).
Exclusion Criteria:
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
- A positive urine drug screen.
- Treatment with an investigational drug within 30 days (or as determined by the local requirement, whichever is longer) or 5 half-lives preceding the first dose of study medication.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Grundvidenskab
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Cohort 1
Subjects will be assigned to receive either PF-03654764 or placebo.
|
5mg orally once daily for 10 days.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
orally once daily for 10 days.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
12mg orally once daily for 10 days.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
12mg orally twice daily on Days 1-9, and once on Day 10 After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
oral twice daily on Days 1-9 and once on Day 10.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
|
|
Eksperimentel: Cohort 2
Subjects will be assigned to receive either PF-03654764 or placebo.
|
5mg orally once daily for 10 days.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
orally once daily for 10 days.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
12mg orally once daily for 10 days.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
12mg orally twice daily on Days 1-9, and once on Day 10 After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
oral twice daily on Days 1-9 and once on Day 10.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
|
|
Eksperimentel: Cohort 3
Subjects will be assigned to receive either PF-03654764 or placebo.
|
5mg orally once daily for 10 days.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
orally once daily for 10 days.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
12mg orally once daily for 10 days.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
12mg orally twice daily on Days 1-9, and once on Day 10 After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
oral twice daily on Days 1-9 and once on Day 10.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
safety & toleration: Adverse events, vital signs, 12 lead ECG, blood and urine safety tests, suicidality assessment using the Suicidality Tracking Scale (STS) and physical examination.
Tidsramme: 10 days
|
10 days
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Plasma pharmacokinetics: Cmax, Tmax, AUCtau, t½, AUCtau (Day 10)/AUCtau (Day 1), CL/F
Tidsramme: 10 days
|
10 days
|
|
Urine pharmacokinetics: Ae24 & Ae24% (for once daily doses) or Ae12 & Ae12% (for twice daily dose) on Day 10, CLR
Tidsramme: 10 days
|
10 days
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. oktober 2009
Primær færdiggørelse (Faktiske)
1. december 2009
Studieafslutning (Faktiske)
1. december 2009
Datoer for studieregistrering
Først indsendt
2. oktober 2009
Først indsendt, der opfyldte QC-kriterier
2. oktober 2009
Først opslået (Skøn)
5. oktober 2009
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
16. december 2009
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
15. december 2009
Sidst verificeret
1. december 2009
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- B0711002
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
produkt fremstillet i og eksporteret fra U.S.A.
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .